Three-Pronged attack on stubborn blood cancers
NCT ID NCT06563596
Summary
This study is testing a combination of three drugs—epcoritamab, zanubrutinib, and rituximab—to see how well they work and how safe they are for people with follicular lymphoma or marginal zone lymphoma that has come back or hasn't responded to previous treatments. About 45 participants will receive the treatment for about a year and then be followed for up to 10 years to monitor their health and the long-term effects of the therapy. The main goal is to see if this combination can lead to a complete disappearance of cancer signs on medical scans.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10021, United States
Contact Email: •••••@•••••
Contact
-
The Ohio State University Wexner Medical Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.